Binge Eating Disorder Clinical Trial
Official title:
Noom Monitor for Binge Eating
NCT number | NCT02555553 |
Other study ID # | GCO 14-1335 |
Secondary ID | |
Status | Completed |
Phase | N/A |
First received | |
Last updated | |
Start date | April 2016 |
Est. completion date | May 1, 2018 |
Verified date | September 2019 |
Source | Icahn School of Medicine at Mount Sinai |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The purpose of the proposed Phase II STTR study is to test the primary efficacy of a novel mobile app, 'Noom Monitor,' in a large population of binge eaters in the Kaiser Permanente health care system relative to a well-established treatment as usual (TAU) control condition. Noom Monitor facilitates the delivery of CBT-GSH by utilizing a patient interface that increases adherence and provides between-session reminders of CBT-GSH principles. In addition, the Noom Monitor includes a therapist interface with weekly feedback to the provider about patient progress. This application has several primary objectives, including: (1) testing the real-world effectiveness of the Noom Monitor in a clinical setting, and (2) establishing a database of training materials for Noom Monitor. The knowledge gained from the current study will contribute to our understanding of the role of new emerging mobile technologies in augmenting existing treatments.
Status | Completed |
Enrollment | 225 |
Est. completion date | May 1, 2018 |
Est. primary completion date | May 1, 2018 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 55 Years |
Eligibility |
Inclusion Criteria: - Meets for DSM-5 BN or BED criteria - Between the ages of 18 and 55 - Males and females - BMI greater than 18.5 and less than 40 - Medical clearance in the case of reported purging or extreme exercise - Free of psychiatric medication for at least 2 weeks prior to study or on a stable dose of medication for 4 weeks - 1 year continuous enrollment in Kaiser Permanente Northwest health plan Exclusion Criteria: - Has undergone bariatric surgery - Demonstrates need for higher level of care (e.g., very low weight (<18.5)) - Current comorbid substance dependence, bipolar or psychotic illness - Current suicidal ideation - Previously received Enhance Cognitive behavioral therapy or Cognitive behavioral therapy-guided self help - Previously read Overcoming Binge Eating by Christopher Fairburn - Purging and/or laxative use more than 2x a day on average over the last month. |
Country | Name | City | State |
---|---|---|---|
United States | Kaiser Permanente Center for Health Research | Portland | Oregon |
Lead Sponsor | Collaborator |
---|---|
Icahn School of Medicine at Mount Sinai | Kaiser Permanente, Noom Inc. |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Objective Binge Days | Objective Binge Days - Objective binge days item of Eating Disorder Examination Scale version 16 (EDE-Q V6) - Frequency of days with objective binge episodes | At 0 week | |
Primary | Objective Binge Days | Objective Binge Days - Objective binge days item of EDE-Q V6 - Frequency of days with objective binge episodes | At 4 weeks | |
Primary | Objective Binge Days | Objective Binge Days - Objective binge days item of EDE-Q V6 - Frequency of days with objective binge episodes | At 8 weeks | |
Primary | Objective Binge Days | Objective Binge Days - Objective binge days item of EDE-Q V6 - Frequency of days with objective binge episodes | At 12 weeks | |
Primary | Objective Binge Days | Objective Binge Days - Objective binge days item of EDE-Q V6 - Frequency of days with objective binge episodes | At 26 weeks | |
Primary | Objective Binge Days | Objective Binge Days - Objective binge days item of EDE-Q V6 - Frequency of days with objective binge episodes | At 52 weeks | |
Primary | Sum of Compensatory Episodes | Sum of days where vomiting, laxative, or compulsive exercise occurs - sum of 3 items on EDE-Q v6 | At 0 week | |
Primary | Sum of Compensatory Episodes | Sum of days where vomiting, laxative, or compulsive exercise occurs - sum of 3 items on EDE-Q v6 | At 4 weeks | |
Primary | Sum of Compensatory Episodes | Sum of days where vomiting, laxative, or compulsive exercise occurs - sum of 3 items on EDE-Q v6 | At 8 weeks | |
Primary | Sum of Compensatory Episodes | Sum of days where vomiting, laxative, or compulsive exercise occurs - sum of 3 items on EDE-Q v6 | At 12 weeks | |
Primary | Sum of Compensatory Episodes | Sum of days where vomiting, laxative, or compulsive exercise occurs - sum of 3 items on EDE-Q v6 | At 26 weeks | |
Primary | Sum of Compensatory Episodes | Sum of days where vomiting, laxative, or compulsive exercise occurs -sum of 3 items on EDE-Q v6 | At 52 weeks | |
Secondary | Clinical Impairment Assessment | Full scale from 0-48, with higher score indicating more impairment | At 0 week | |
Secondary | Clinical Impairment Assessment | Full scale from 0-48, with higher score indicating more impairment | At 4 weeks | |
Secondary | Clinical Impairment Assessment | Full scale from 0-48, with higher score indicating more impairment | At 8 weeks | |
Secondary | Clinical Impairment Assessment | Full scale from 0-48, with higher score indicating more impairment | At 12 weeks | |
Secondary | Clinical Impairment Assessment | Full scale from 0-48, with higher score indicating more impairment | At 26 weeks | |
Secondary | Clinical Impairment Assessment | Full scale from 0-48, with higher score indicating more impairment | At 52 weeks | |
Secondary | Personal Health Questionnaire | Full scale from 0-24, with higher score indicating more depression | At 0 weeks | |
Secondary | Personal Health Questionnaire | Full scale from 0-24, with higher score indicating more depression | At 4 weeks | |
Secondary | Personal Health Questionnaire | Full scale from 0-24, with higher score indicating more depression | At 8 weeks | |
Secondary | Personal Health Questionnaire | Full scale from 0-24, with higher score indicating more depression | At 12 weeks | |
Secondary | Personal Health Questionnaire | Full scale from 0-24, with higher score indicating more depression | At 26 weeks | |
Secondary | Personal Health Questionnaire | Full scale from 0-24, with higher score indicating more depression | At 52 weeks | |
Secondary | Quality of Life Scale | Full scale from 16-112, with higher score indicating better health outcomes | At 0 week | |
Secondary | Quality of Life Scale | Full scale from 16-112, with higher score indicating better health outcomes | At 4 weeks | |
Secondary | Quality of Life Scale | Full scale from 16-112, with higher score indicating better health outcomes | At 8 weeks | |
Secondary | Quality of Life Scale | Full scale from 16-112, with higher score indicating better health outcomes | At 12 weeks | |
Secondary | Quality of Life Scale | Full scale from 16-112, with higher score indicating better health outcomes | At 26 weeks | |
Secondary | Quality of Life Scale | Full scale from 16-112, with higher score indicating better health outcomes | At 52 weeks | |
Secondary | Eating Concern Subscale | Eating concern subscale of the EDE-QV6 from 0-6 with higher score indicating worse health outcomes | At 0 week | |
Secondary | Eating Concern Subscale | Eating concern subscale of the EDE-QV6 from 0-6 with higher score indicating worse health outcomes | At 4 weeks | |
Secondary | Eating Concern Subscale | Eating concern subscale of the EDE-Q v6 from 0-6 with higher score indicating worse health outcomes | At 8 weeks | |
Secondary | Eating Concern Subscale | Eating concern subscale of the EDE-Q v6 from 0-6 with higher score indicating worse health outcomes | At 12 weeks | |
Secondary | Eating Concern Subscale | Eating concern subscale of the EDE-Q v6 from 0-6 with higher score indicating worse health outcomes | At 26 weeks | |
Secondary | Eating Concern Subscale | Eating concern subscale of the EDE-Q v6 from 0-6 with higher score indicating worse health outcomes | At 52 weeks | |
Secondary | Dietary Restraint Subscale | Dietary Restraint Subscale of the EDE-Q v6 from 0-6, with higher score indicating worse health outcomes | At 0 week | |
Secondary | Dietary Restraint Subscale | Dietary Restraint Subscale of the EDE-Q v6 from 0-6, with higher score indicating worse health outcomes | At 4 weeks | |
Secondary | Dietary Restraint Subscale | Dietary Restraint Subscale of the EDE-Q v6 from 0-6, with higher score indicating worse health outcomes | At 8 weeks | |
Secondary | Dietary Restraint Subscale | Dietary Restraint Subscale of the EDE-Q v6 from 0-6, with higher score indicating worse health outcomes | At 12 weeks | |
Secondary | Dietary Restraint Subscale | Dietary Restraint Subscale of the EDE-Q v6 from 0-6, with higher score indicating worse health outcomes | At 26 weeks | |
Secondary | Dietary Restraint Subscale | Dietary Restraint Subscale of the EDE-Q v6 from 0-6, with higher score indicating worse health outcomes | At 52 weeks | |
Secondary | Shape Concern Subscale | Shape Concern Subscale of the EDE-Q v6 from 0-6, with higher score indicating worse health outcomes | At 0 week | |
Secondary | Shape Concern Subscale | Shape Concern Subscale of the EDE-Q v6 from 0-6, with higher score indicating worse health outcomes | At 4 weeks | |
Secondary | Shape Concern Subscale | Shape Concern Subscale of the EDE-Q v6 from 0-6, with higher score indicating worse health outcomes | At 8 weeks | |
Secondary | Shape Concern Subscale | Shape Concern Subscale of the EDE-Q v6 from 0-6, with higher score indicating worse health outcomes | At 12 weeks | |
Secondary | Shape Concern Subscale | Shape Concern Subscale of the EDE-Q v6 from 0-6, with higher score indicating worse health outcomes | At 26 weeks | |
Secondary | Shape Concern Subscale | Shape Concern Subscale of the EDE-Q v6 from 0-6, with higher score indicating worse health outcomes | At 52 weeks | |
Secondary | Weight Concern Subscale | Weight Concern Subscale of the EDE-Q v6 from 0-6, with higher score indicating worse health outcomes | At 0 Week | |
Secondary | Weight Concern Subscale | Weight Concern Subscale of the EDE-Q v6 from 0-6, with higher score indicating worse health outcomes | At 4 Weeks | |
Secondary | Weight Concern Subscale | Weight Concern Subscale of the EDE-Q v6 from 0-6, with higher score indicating worse health outcomes | At 8 Weeks | |
Secondary | Weight Concern Subscale | Weight Concern Subscale of the EDE-Q v6 from 0-6, with higher score indicating worse health outcomes | At 12 Weeks | |
Secondary | Weight Concern Subscale | Weight Concern Subscale of the EDE-Q v6 from 0-6, with higher score indicating worse health outcomes | At 26 Weeks | |
Secondary | Weight Concern Subscale | Weight Concern Subscale of the EDE-Q v6 from 0-6, with higher score indicating worse health outcomes | At 52 Weeks | |
Secondary | Global Eating Disorder Subscale | Global Eating Disorder Subscale of the EDE-Q v6 from 0-6, with higher score indicating worse health outcomes | At 0 week | |
Secondary | Global Eating Disorder Subscale | Global Eating Disorder Subscale of the EDE-Q v6 from 0-6, with higher score indicating worse health outcomes | At 4 weeks | |
Secondary | Global Eating Disorder Subscale | Global Eating Disorder Subscale of the EDE-Q v6 from 0-6, with higher score indicating worse health outcomes | At 8 weeks | |
Secondary | Global Eating Disorder Subscale | Global Eating Disorder Subscale of the EDE-Q v6 from 0-6, with higher score indicating worse health outcomes | At 12 weeks | |
Secondary | Global Eating Disorder Subscale | Global Eating Disorder Subscale of the EDE-Q v6 from 0-6, with higher score indicating worse health outcomes | At 26 weeks | |
Secondary | Global Eating Disorder Subscale | Global Eating Disorder Subscale of the EDE-Q v6 from 0-6, with higher score indicating worse health outcomes | At 52 weeks |
Status | Clinical Trial | Phase | |
---|---|---|---|
Withdrawn |
NCT02978742 -
Evaluating and Implementing a Smartphone Application Treatment Program for Bulimia Nervosa and Binge Eating Disorder
|
N/A | |
Recruiting |
NCT02659488 -
Lisdexamfetamine in Binge Eating Disorder (BED): fMRI Effects
|
Phase 2 | |
Completed |
NCT02659475 -
Phentermine/Topiramate Extended Release in Binge Eating Disorder (BED)
|
Phase 2 | |
Completed |
NCT00601653 -
Effectiveness of Cognitive Behavioral Therapy Plus Nutritional Counseling in Promoting Weight Loss in People With Binge Eating Disorder
|
N/A | |
Completed |
NCT02834299 -
Dialectical Behavior Therapy Guided Self-Help for Binge Eating Disorder
|
N/A | |
Completed |
NCT02553824 -
FDA Approved Medication to Reduce Binge Eating and/or Purging
|
Phase 1 | |
Completed |
NCT02564588 -
Dasotraline Binge Eating Disorder Study
|
Phase 2/Phase 3 | |
Completed |
NCT00307190 -
Hormone Release and Stomach Disturbances in People With Binge Eating Disorder
|
N/A | |
Completed |
NCT01718509 -
SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
|
Phase 3 | |
Completed |
NCT01718483 -
SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
|
Phase 3 | |
Completed |
NCT02503098 -
Optimizing a Smartphone Application for Individuals With Eating Disorders
|
N/A | |
Active, not recruiting |
NCT01837953 -
Stepped Care for Binge Eating Disorder: Predicting Response to Minimal Intervention in a Randomized Controlled Trial
|
N/A | |
Completed |
NCT01010789 -
Armodafinil in Binge Eating Disorder (BED)
|
Phase 3 | |
Completed |
NCT01098435 -
ALK33-101: A Study of RDC-0313 (ALKS 33) in Adults With Binge Eating Disorder
|
Phase 2 | |
Completed |
NCT01552759 -
Appetite Hormones in Binge Eating Disorder
|
N/A | |
Completed |
NCT00330655 -
An Open-Label Trial of Memantine in the Treatment of Binge Eating Disorder
|
Phase 4 | |
Completed |
NCT01291173 -
Forced-dose Titration of SPD489 in Adults With Binge Eating Disorder
|
Phase 2 | |
Completed |
NCT03107026 -
A Study to Evaluate a Drug (Dasotraline) on the Safety, Effectiveness and How Well the Body Tolerates it, in Adults With Moderate to Severe Binge Eating Disorder
|
Phase 3 | |
Completed |
NCT02079935 -
Treatment of Eating Disorders by Physical Activity and Nutrition Counseling
|
N/A | |
Completed |
NCT00277641 -
Lamotrigine in the Treatment of Binge Eating Disorder Associated With Obesity
|
Phase 3 |